Aadi Bioscience, Inc.

AADI

US00032Q1040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.78 ^USD	-3.26%		-2.20%	-11.88%

Mar. 13	Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Mar. 13	Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	MT

Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 10, 2022 at 08:14 am EDT

Aadi Bioscience, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 3.44 million. Net loss was USD 18.27 million compared to USD 1.54 million a year ago. Basic loss per share from continuing operations was USD 0.87.
For the six months, revenue was USD 5.74 million compared to USD 0.12 million a year ago. Net loss was USD 32.13 million compared to USD 7.01 million a year ago. Basic loss per share from continuing operations was USD 1.53.

Latest news about Aadi Bioscience, Inc.

Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M	Mar. 13	MT
Aadi Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
North American Morning Briefing : Stock Futures Hover At Start of Busy Week	Mar. 04	DJ
Aadi Bioscience Reports Supportive Data from Tumor Treatment Trial -- Shares Jump After Hours	Mar. 01	MT
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
Sector Update: Health Care Stocks Retreating Late Afternoon	Dec. 15	MT
Top Midday Decliners	Dec. 15	MT
Piper Sandler Cuts Aadi Bioscience's Price Target to $5 From $30, Keeps Overweight Rating	Dec. 15	MT
Wall Street Set to Open Narrowly Mixed Ahead of PMI, Industrial Production Data	Dec. 15	MT
Top Premarket Decliners	Dec. 15	MT
HC Wainwright Downgrades Aadi Bioscience to Neutral From Buy	Dec. 15	MT
Transcript : Aadi Bioscience, Inc. - Special Call	Dec. 14
Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations	Dec. 14	CI
Aadi Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Transcript : Aadi Bioscience, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $6M	Nov. 08	MT
Aadi Bioscience Insider Sold Shares Worth $185,750, According to a Recent SEC Filing	Nov. 03	MT
Aadi Bioscience Insider Sold Shares Worth $179,001, According to a Recent SEC Filing	23-10-04	MT
Aadi Bioscience Names Dave Lennon as CEO	23-10-02	MT
Aadi Bioscience, Inc. Announces Executive Changes	23-10-02	CI
Aadi Bioscience, Inc. Announces Chief Executive Officer Changes	23-10-02	CI
Transcript : Aadi Bioscience, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 09:30 AM	23-09-13
Aadi Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI

Chart Aadi Bioscience, Inc.

Duration

Period

More charts

Company Profile

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aadi Bioscience, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.78 USD

Average target price

11.67 USD

Spread / Average Target

+555.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AADI BIOSCIENCE, INC.	-11.88%	43.71M
CSL LIMITED	-2.86%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+3.95%	40.86B
BIOGEN INC.	-21.94%	29.36B
UCB	+53.11%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-5.41%	17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.23%	11.26B
INCYTE CORPORATION	-17.60%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.96%	11.31B
SWEDISH ORPHAN BIOVITRUM AB	-0.22%	8.31B

Biopharmaceuticals